Physician profile
Jamie Elizabeth Sison
NPI 1336880681
$1,639.57
in general payments reported to CMS, 2019-2025
14 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $359 · 2024: $339 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071 · Travel and Lodging: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.00 |
| Travel and Lodging | $318.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $531.16 | 2025 | Blue Rhino |
| Astrazeneca Pharmaceuticals LP | $249.29 | 2022-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $159.00 | 2023 | Ultomiris |
| Medtronic, INC. | $146.41 | 2024 | Linq II |
| E.R. Squibb & Sons, L.L.C. | $146.31 | 2022-2023 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $122.94 | 2025 | Opsumit, Uptravi |
| Shionogi INC | $121.73 | 2024 | Fetroja |
| La Jolla Pharmaceutical Company | $61.82 | 2023-2024 | Xerava, Giapreza |
| Tetraphase Pharmaceuticals, INC. | $20.08 | 2025 | |
| Chiesi USA, INC. | $18.26 | 2025 | Cleviprex |
| Melinta Therapeutics, LLC | $18.06 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Aurinia Pharma U.S., INC. | $16.20 | 2024 | Lupkynis |
| Exact Sciences Corporation | $14.45 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.86 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Sison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.